Cure4 Cystic Fibrosis Foundation

Behind every event, appeal, campaign and milestone at Cure4CF are people and businesses who help make it all possible. Johns' Print Centre is one of those.

From event signage and campaign materials to the countless print jobs that help us connect with our community, the Johns Print team consistently delivers outstanding work. Their support has helped us share stories, engage supporters and raise vital funds for cystic fibrosis research.

As a small charity, partnerships like this mean more than we can put into words. Working with trusted local businesses helps us bring our campaigns and events to life while keeping our focus firmly on funding research that brings us closer to a cure.

To everyone at Johns Print Centre, thank you for being part of the Cure4CF community and for supporting our mission. We are incredibly grateful. 🧡

Cystic fibrosis doesn’t wait.
It becomes part of life immediately.

Treatments before school. Medications before breakfast. Hospital visits. Daily therapies. The constant responsibility of protecting fragile lungs from infection. For children like Simon, this is simply normal life.

But thanks to research, there is more hope than there once was.
Better understanding. Better treatments. New research is changing what life with CF can look like.

And every breakthrough begins the same way — because someone chooses to make it possible.

This EOFY, your support can help fund the vital research that will create a better future for people living with CF.

A gift of $66 can fund one hour of research.
One hour closer to better treatments.
One hour closer to longer lives.
One hour closer to changing what a CF diagnosis means for families like Simon’s.

Donate by June 30: https://tinyurl.com/simons-story

As I head back to Australia today, it has been great to spend some time reflecting on this year’s ECFS Conference.

It’s always inspiring to see the breadth of work happening across the global CF community.

A few themes that stood out for me:

🧬 Gene therapy progress continues
Research in the gene therapy space is moving forward, with many studies underway. It was a timely reminder that bringing a new treatment from the laboratory to the clinic takes years of dedicated work, collaboration, and persistence—but progress is happening.
🦠 Infection remains an important focus
New data confirmed that while many people are producing less sputum than before, harmful bacteria can still be present in the lungs. Understanding and managing infection continues to be a critical area of CF research.
🍽️ Growing focus on gut health
There was significant attention on the impact of CF on the gastrointestinal tract, highlighting growing recognition of the importance of digestive health and opportunities for future research, including here in Australia.
🧠 Neurodiversity and CF
An emerging area of interest was the intersection between neurodivergence and cystic fibrosis. Studies suggest that ADHD symptoms may be associated with quality of life, lung function, BMI and antibiotic use. One of the most powerful messages was that neurodivergence is not something to be "fixed"—instead, we should focus on creating environments that help people thrive. Simple changes to improve predictability, comfort and inclusion can make a meaningful difference to healthcare experiences.

I’m looking forward to sharing more insights from the conference and exploring how these learnings can help shape future research priorities in Australia.

– Professor Jodie Simpson
Head of Research, Cure4CF

Please join us in welcoming the newest members of the Cure4CF Board. 🧡

We are delighted to welcome Greg Knagge and Georgina Liew, who joined the Board in April, bringing valuable expertise, leadership and strategic insight to our organisation.

We also warmly welcome Dr Bernadette Prentice, who joined the Board in December. Dr Prentice brings extensive clinical and research expertise, along with a strong commitment to improving outcomes for people living with cystic fibrosis (CF).

Our Board plays a vital role in guiding Cure4CF’s mission to accelerate research and drive meaningful change for the CF community.

We would also like to sincerely thank outgoing Director Clinton Jury for his eight years of dedicated service, leadership and contribution to Cure4CF. Clinton’s commitment to our mission and the CF community has helped shape our organisation’s growth and impact, and we are grateful for all he has given.

Please join us in welcoming Greg, Georgina and Bernadette, and thanking Clinton for his contribution. 🧡

"I wanted to share some really promising news from the European CF Conference today. Two studies—one from the UK and one from Belgium—looked at kids with CF who had adverse events on their modulator therapy.

What’s amazing is that when they reduced the dose, these children saw fewer adverse events, especially in their mental well-being—while still keeping all the benefits of the treatment.

I know many families are weighing these choices, and I hope this offers some hope and a new perspective.

Let’s keep the conversation going!"

Cure4CF Head of Research - Professor Jodie Simpson

Today at the European Cystic Fibrosis Conference, we learned from a UK study of 159 adults with CF about a big question: to switch or not to switch from Trikafta to the new therapy, Alyftrek.

Around 78 participants switched, and the rest stayed on Trikafta.

Many stayed with Trikafta because they felt stable, while others preferred Alyftrek often due to taking it once daily or managing side effects.

After three months, no major differences were seen in lung function or BMI, but some did see improved liver function. Importantly, a small group did experience significant side effects and switched back.

This research is so valuable as we navigate this new era of CF care—not medical advice, but a chance to reflect: if you’re on Trikafta, or thinking of switching, what factors would you consider?

For families living with cystic fibrosis, treatments are not occasional. They are everyday life. For Simon, airway clearance therapy is part of his daily routine — essential treatments designed to help keep his lungs clear and protect his breathing.

Like many people living with CF, the process can be exhausting. Time-consuming. Relentless.

Recently, Simon gained access to a specialised therapy device called the Pegaso cough assist system. For Simon and his family, the difference has been significant.

Treatments have become more effective. Less physically demanding. Easier to manage at home.

Moments like this matter deeply to families living with CF. Because behind every improvement is something powerful: hope.

Hope that treatments can become easier.
Hope that quality of life can improve.
Hope that children growing up with CF may face a different future than generations before them.

But access to therapies like this remains limited.

This EOFY, your support can help fund vital research working to improve access and change lives for more people living with CF.

Because what is helping Simon today could help many more families tomorrow.
Please donate now: https://tinyurl.com/simons-story

Cure4CF CEO Suzy Dimaline, and Head of Research Professor Jodie Simpson are attending the 49th European Cystic Fibrosis Conference in Lisbon this week.

Events like ECFS play an important role in bringing together the global CF community to learn, collaborate and share emerging research, clinical practice and innovation.

For organisations like Cure4CF, they are also an invaluable opportunity to listen, build relationships and gain insights that can help inform where investment, collaboration and research funding can have the greatest impact.

They're looking forward to a week of learning and bringing key insights home.

Thanks to our amazing donor who has funded their attendance to the conference.